Name	Position	Tenure	Compensation	Ownership
Z. Rosado	Interim CFO & Director	2.1yrs	US$1.51m	no data
Senthil Ranganathan	Vice President of Technical Operations	1.7yrs	no data	no data
David Russ	Vice President of Supply Chain	1.7yrs	no data	no data
Manal Morsy	Executive VP & Head of Global Regulatory Affairs	11.7yrs	no data	no data
Robert Mays	Executive VP	8.2yrs	no data	no data
Rakesh Ramachandran	Head of Information Technology & Communications and VP	7.7yrs	no data	no data
Sarah Busch	VP of Regenerative Medicine & Head of Business Development	1.7yrs	no data	no data
Ellen Gurley	Manager of Corporate Communications and Investor Relations	no data	no data	no data

2.1yrs

Average Tenure

Experienced Management: ATHX.Q's management team is considered experienced (2.1 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/25 12:54
End of Day Share Price	2024/09/25 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Athersys, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Gregory Harrison	BofA Global Research
Raymond Deacon	Brean Capital

This company listing is no longer active

Athersys Management

Management criteria checks 1/4

Key information

Recent management updates

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

CEO, Secretary recently bought US$55k worth of stock

Recent updates

Motion For Case Conversion Approved for Athersys, Inc.

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

CEO, Secretary recently bought US$55k worth of stock

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Kasey Rosado named interim CFO of Athersys

Athersys: Dead Man Walking

Consensus forecasts updated

Athersys: Focus On Stroke

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Consensus forecasts updated

Consensus forecasts updated

Athersys: Subgroup Analysis As A Masterstroke

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

Consensus revenue estimates fall to US$9.42m

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

New 90-day high: US$2.44

New 90-day high: US$2.24

New 90-day low: US$1.55

Analysts lower revenue estimates to US$281.5k

Earnings beat expectations, revenue disappoints

New 90-day low: US$1.79

CEO

Leadership Team

Average Tenure

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources